25 - Hyperlipidemia Treatment Flashcards

1
Q

What is a dyslipidemia?

A

Dyslipidemia: disorder of lipid and lipoprotein absorption and synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are lipoproteins?

A

Lipoproteins = cholesterol transport mechanisms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is LDL-C and HDL-C? Triglycerides?

A
  • LDL-C: Low Density Lipoprotein – Cholesterol
  • HDL-C: High density Lipoprotein – Cholesterol
  • Triglycerides: fatty acid
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

There is a clear causal relationship between dyslipidemia and…

A

CAD - coronary artery disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

There is a clear benefit in dyslipidemias by lowering…

A

Serum cholesterol (total LDL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the leading cause of death in the US?

A

Heart disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the general concept between the ACC/AHA guidelines for treating hyperlipidemias?

A
  • There seems to be no evidence supporting a treatment plan which aims to lower cholesterol to a certain level
  • Instead, treating with the appropriate intensity of statin therapy has been shown to reduce cardiovascular risk
  • This means that you titrate the intensity of the therapy to the degree of risk the patient is at, don’t just aim to hit a certain cholesterol level
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is a “primary strategy” in treating hyperlipidemia?

A

Preemptive treatment of high risk persons before any disease state has developed
- Primary is based on the risk level of the patient, so you are trying to push the first event back as far as possible, based on their risk level **

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is a “secondary strategy” in treating hyperlipidemia?

A

Repeat treatment in known disease state

  • Secondary means you’re too late – they already have the disease, you’re trying to prevent the next event or progression **
  • Statins drug of choice; others might work (less robust evidence)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is a “pooled cohort risk assessment”?

A

“Pooled Cohort Risk Assessment Equations”

  • Developed by the Risk Assessment Work Group to estimate 10-year risk*
  • 10-year risk for (ASCVD): coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke
  • Can use online calculator for equation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the basic principle of dyslipidemia risk assessment?

A

Calculate 10 year risk, let treatment titration follow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the factors that the risk assessment considers?

A

Risk influenced by age, gender, and other risk factors:
Hypertension
Smoking
Family history (premature CHD in first-degree relative)
* Diabetes not usually considered in screening guidelines for primary prevention (risk of CHD is known to be high)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe a high risk patient

A

Patients at higher risk generally have several risk factors or a single severe risk factor (e.g. patient siblings with CHD in their 40s or very heavy smoking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the major risk factors outside of high cholesterol?

A
  • Cigarette smoking
  • Hypertension (BP 140/90 mmHg or needing meds)
  • If you don’t need meds, you decrease your risk - this is a goal
  • Diabetes mellitus
  • Family history of premature CAD
  • CAD in male first degree relative
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

When would it be reasonable to do a lipid screening?

A
  • Adults ages 20 to 79, free from CVD with risk factors (smoking, HTN, diabetes, total cholesterol, HDL-C)
  • Every 4 to 6 years to calculate 10-year CVD risk
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

When would you possibly consider doing a lipid screening?

A
  • Adults 20 – 59, free from CVD without other risks (10 year
17
Q

What do you need to remember about diabetes and ASCVD?

A

ASCVD = atherosclerotic cardiovascular disease

Diabetes is not a “risk factor” it IS the disease

Remember: Diabetes = known ASCVD!

18
Q

When you get a 7.5% or lower chance of an ASCVD in the next 5 years, what do you do?

A

Tell the patient to keep up the good work

19
Q

What is the drug of choice for dyslipidemia treatment?

A

HMG-CoA inhibitors (statins)

20
Q

What are the 4 major benefits of statins?

A

1 - Effective in secondary prevention of all individuals with clinical cardiovascular disease
2 - Effective in primary prevention for patients with isolated LDL-C
3 - Effective in primary prevention for patients with diabetes, 40-75 yo and LDL-C elevation
4 - Effective in primary prevention for patients with a 10-year CVD risk of greater than 7.5%, 40-75 yo and LDL-C elevation

21
Q

What is the primary prevention of LDL-lowering therapy?

A

Public health approach is mostly education - NON-DRUG

  • Address lipid levels in asymptomatic (presumably disease-free) individuals
  • Increase physical activity (aerobic)
  • Weight control (BMI
22
Q

What is the secondary prevention of LDL-lowering therapy?

A

Non-drug

  • Increase physical activity (aerobic)
  • Weight control (if BMI>25)
  • Dietary modification to reduce intake of saturated fat and cholesterol
  • Control of other ASCVD risk factors

Drug of choice

  • Statins *** (moderate or high intensity)
  • Moderate intensity in 75+
  • High intensity in
23
Q

What are the benefits of statin drug therapy?

A
  • reduced total mortality & coronary mortality
  • fewer major coronary events
  • fewer coronary procedures
  • reduced incidence of stroke
24
Q

What are side effects of statins?

A

= Myopathy

- Increased liver enzymes

25
Q

What are the contraindications of statins?

A
  • Absolute: liver disease
  • Relative: use with certain drugs
  • Not-recommended: with class II-IV heart failure drugs or patients on hemodialysis